Boey (trenibotulinumtoxinE)

Where it stands

Boey (trenibotulinumtoxinE) is authorised in the EU. The European Commission decision was dated 2026-07-15, and the marketing authorisation holder is AbbVie Limited. The CHMP adopted a positive opinion on 2026-05-21.

The approved indication is the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines). This applies only when the lines have an important psychological impact, and only in adults. That qualifier is part of the wording and narrows the label beyond a purely aesthetic claim.

The records list the therapeutic areas as 'Stress, Psychological' and 'Cosmetic Techniques'. They do not give launch timing, member-state availability, pack presentations or pricing and reimbursement status.

Regulatory pathway and designations

The records show two milestones: the CHMP positive opinion on 2026-05-21 and the EC approval on 2026-07-15. That is 55 days between them. In general, the Commission issues its decision after the CHMP opinion, normally within about 67 days. The interval here is consistent with that standard step, though the records do not describe any procedural detail.

The only designation recorded is additional monitoring. In the EU this means the product is included in the list of medicines under additional monitoring and carries a black inverted triangle in its product information. It is typically applied to newly authorised active substances and to products with specific post-authorisation requirements. The records do not say which applies to Boey.

The records do not mention orphan status, PRIME, accelerated assessment, conditional approval or exceptional circumstances. They also do not give the legal basis of the application or the assessment timetable, so none of these should be assumed.

Safety and pharmacovigilance

The records contain no safety data. They give no adverse-event profile, contraindications, warnings, risk management plan content or conditions of the authorisation. This analysis cannot characterise Boey's safety profile.

Additional monitoring means suspected adverse reactions are actively encouraged to be reported by healthcare professionals and patients, so the safety profile can be refined as real-world exposure accumulates. It does not by itself indicate a specific safety concern.

The product name points to a botulinum toxin. Botulinum toxin products generally carry class-related warnings, for example on effects spreading beyond the injection site. The records do not confirm which warnings, if any, appear in Boey's product information. Readers should consult the EPAR and SmPC for the authoritative text.

What to watch

Check the published EPAR and product information for the efficacy and safety evidence, dosing, the treatment-interval wording, and any risk-minimisation measures. The records do not contain these.

Also watch how the 'important psychological impact' criterion is interpreted in practice, since it defines the eligible population in the label. National launches, reimbursement positions and any additional-monitoring reporting trends would come later and are not covered by the records.

For competitive and business-development assessment, comparison with other authorised glabellar-line treatments would require data outside these records. No such comparison is made here.